Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

February 2, 2022

Conditions
SARS-CoV-2 Infection
Interventions
DRUG

Nitric Oxide

The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.

Trial Locations (21)

302039

Maharaja Agrasen Superspeciality Hospital, Jaipur

400001

St. Georges Hospital, Mumbai

400099

Dr Rahul Kodgule, Mumbai

411047

Orchid Specialty Hospital, Lohgaon

411057

Lifepoint Multispeciality Hospital, Pune

415409

Prakash Institute of Medical Sciences & Research, Islāmpur

416002

Pharmacology Dept. CPR Hospital Campus, Town Hall,, Kolhāpur

431002

Ishwar Institute & Hospital, Aurangabad

431003

MGM Medical College & Hospital, Aurangabad

440003

Government Medical College and Hospital Nagpur, Nagpur

441108

All India Institute of Medical Sciences, Nagpur

500018

St.Theresas Hospital, Hyderabad

500038

Aster Prime Hospital, Hyderabad

560002

Bangalore Medical College and Research Institute, Bangalore

641028

Hindusthan Hospital, Coimbatore

673323

Malabar Medical College Hospital and Research Centre, Kozhikode

700027

C K Birla Hospitals, The Calcutta Medical Research Institute, Kolkata

700094

Peerless Hospitex Hospital And Research Centre Limited, Kolkata

781008

Marwari Hospital, Guwahati

Unknown

Renova Neelima Hospitals, Hyderabad

CSI Medical College and Hospital, Kolkata

Sponsors
All Listed Sponsors
collaborator

Glenmark Pharmaceuticals Ltd. India

INDUSTRY

lead

Sanotize Research and Development corp.

INDUSTRY